EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.